

AMR SURVEILLANCE NETWORKS

PUBLIC-PRIVATE PARTNERSHIPS FOR THE DEVELOPMENT AND STRENGTHENING OF INFORMATION SYSTEMS.

The Biomérieux logo is a semi-circle with a blue top half and a yellow-to-green gradient bottom half. The word "BIOMÉRIEUX" is written in white, uppercase letters across the blue section.

Gabriel PEDONE - Global Health Partnerships Director

MEDELLIN - July 12th, 2023



ACKNOWLEDGEMENTS TO DR. PILAR RAMON & MARCELO GALAS FOR THE INVITATION AND THE OPPORTUNITY TO PRESENT ON HOW A PRIVATE COMPANY CAN CONTRIBUTE TO GLOBAL EFFORTS TO COMBAT ANTIMICROBIAL RESISTANCE (AMR)

***PRESENTATION MADE ON BEHALF
OF LATAM BIOMERIEUX TEAM***



AGENDA



- **Ecology of the local healthcare institution (lab/hospital)**



- **AMR Surveillance Networks (public health officials)**

ECOLOGY OF THE LOCAL HEALTHCARE INSTITUTION (HOSPITAL)




REAL™



Lab Analytics



FROM CLINICIAN DEMANDS TO DATA SURVEILLANCE



HIS - LIS

MIDDLEWARE

HIS - LIS

Surveillance Software

A SCALABLE SOLUTION: FROM LOCAL HEALTHCARE INSTITUTIONS (HOSPITAL) TO PUBLIC HEALTH OFFICIALS



One single REAL™



REAL™



CLARION™
Lab Analytics




Microbiology analytical workflow



AMS & lab performance



Multi Real™



AMR surveillance networks



Epidemiology monitoring

Data volume



¿QUÉ ES R·E·A·L?



Information management system for **infectious disease management**, which integrates with the hospital environment and facilitates **timely clinical decisions**, through **optimized workflows** and **superior connectivity**.

WHAT MIDDLEWARE OFFER ? RELEVANT INFORMATION & MICROBIOLOGICAL STATISTICS FOR CLINICAL DECISION MAKING


- Lab Manager dashboard: Allows to display the main KPIs (Key Performance Indicators) to deliver the current view of the lab activity (“what happen on my lab”),
- Blood culture dashboards:
 - **Analysis**: positivity rate analysis,
 - **Efficiency**: insight into efficiency of blood culture workflow including mean load time and instrument capacity,
 - **Bottle volume**: blood volume assessment,
 - **Contaminants**: contamination rate analysis,
- ID & AST dashboards:
 - **Analysis**: organisms found in the lab and their associated susceptibility profile,
 - **Organism trend**: trending of organism occurrence,
 - **MDRO phenotype**: trending of resistance patterns,
- Cumulative antibiogram: epidemiology / AMS
 - **Cumulative antibiogram** as the view of the ecosystem of the institution in order to improve empiric antibiotherapy (probabilist antibiotherapy),
- Lab Performance dashboards:
 - **Lab efficiency**: time to results and lab efficiency analysis,
 - **Gram staining**: insight as to the Gram staining step of the microbiology lab workflow,
 - **Vitek MS Spotting analysis**: efficiency and quality of the VITEK MS spotting activity.



“ I NEED AMR SURVEILLANCE ON VRE (VANCOMYCIN RESISTANT ENTEROCOCCUS) ”



BIOMÉRIEUX




Deliver a global view of organisms found in the lab and their associated susceptibility profile.

“ IS THE SUDDEN INCREASE IN ACINETOBACTER BAUMANNII CASES LINKED TO HAI? ”



BIOMÉRIEUX



Deliver trending of organism occurrence.

CUMULATIVE ANTIBIOGRAM



BIOMÉRIEUX

CLARION™ Lab Analytics 5.0 - Cumulative Antibigram | Sheet

Prepare Data manager | Analyze Sheet | Narrate Storytelling | CLARION™ Lab Analytics 5.0

Antibiotic 13 of 59 | Organism 8 of 836

CLARION™ Lab Analytics Cumulative Antibigram

Date Collected | Date Determined | Institution | Specimen Type Group | Organism | Antibiotic Family | Antibiotic | Resistance phenot... | MDRO

I | I as R | I as S | 3M | 6M | 1Y | 2Y | All | Deduplicate

Antibiotic susceptibility (number of isolates)

Organism	AMINOGLYCOSIDES		BETA-LACTAMS				
	Amikacin	Gentamicin	Ampicillin	Cefepime	Cefoxitin	Ceftazidime	Ertapenem
Enterobacter cloacae	88.2% (3,974)	78.3% (3,978)	1.6% (576)	51.9% (1,337)	0.2% (3,972)	49.4% (3,973)	74.5% (3,973)
Enterococcus faecalis	-	-	99.1% (5,458)	-	-	-	-
Enterococcus faecium	-	-	19.4% (1,887)	-	-	-	-
Escherichia coli	97.4% (41,090)	94.1% (41,106)	46.2% (41,074)	81.1% (4,531)	92.9% (41,066)	91.7% (41,082)	99.0% (41,039)
Klebsiella oxytoca	91.7% (2,022)	86.0% (2,024)	0.2% (2,024)	67.5% (425)	88.9% (2,023)	83.3% (2,024)	92.1% (2,024)
Klebsiella pneumoniae	89.9% (9,197)	79.3% (9,198)	0.1% (9,191)	56.7% (1,903)	85.7% (9,193)	66.7% (9,198)	94.1% (9,192)
Proteus mirabilis	98.5% (4,289)	86.1% (4,291)	55.8% (4,287)	96.5% (230)	97.5% (4,286)	98.4% (4,287)	99.1% (4,285)
Pseudomonas aeruginosa	88.4% (8,009)	86.7% (8,014)	-	81.6% (7,917)	-	82.2% (7,999)	-

Date of data collection : 6/8/22 2:57 PM (UTC)

Legend: ≥ 90% | 90% - 70% | < 70% | < 30 isolates

Deliver a view of the ecology of the hospital

AMR SURVEILLANCE NETWORKS



AMR Surveillance networks



CLARION™ AMR SURVEILLANCE NETWORKS - DEFINITION

AMR surveillance is a critical tool for clinicians and public health officials to improve AMS strategy.

An important cornerstone in the control of AMR is a well-designed **quantitative** system for the surveillance of spread and temporal trends in AMR from local healthcare institution (hospital) to a larger area (large cities, provinces, countries).

This AMR surveillance tool must also be **qualitative** and so based on **standardized** routine data from microbiological laboratories (result deduplication, data mapping, breakpoints...).

A **high frequency** (e.g. monthly based) surveillance supports the possibility of detection of resistance evolution that may be more accurate by merging the AMR surveillance data from microbiological laboratories of a large area.

CLARION™ AMR SURVEILLANCE NETWORKS - MOCKUP


- Temporal and geographical trends in AMR from local healthcare institution (hospital) to a larger area (large cities, provinces, countries).

No PHI
No Patient Health Information

Yearly/monthly
trend
Drill down capability

Geo-mapping
Drill down capability

Export data
Graphics and row data




BIOMÉRIEUX

This mockup is not contractual and does not constitute any commitment. The data that are present into the demonstration platform are demonstration data and are not meant to give any clinical considerations, only to demonstrate the capabilities of the tool.

CLARION™ AMR SURVEILLANCE NETWORKS

HOW IT WORKS: OUR AMBITION FOR PILOT SITES



CN
AMR Surveillance network

AMR Surveillance network

Partnership starting 2022




National Cloud Hosting

HIPAA and GDPR compliant




On premise



Local AMR Surveillance

Existing module

OVERVIEW OF CURRENT SURVEILLANCE DATA WORKFLOW/ MALAWI EXAMPLE




National Data Warehouse

DATA CONSOLIDATION

Antibiograms are produced **every quarter** for each of the sites & general overview of all sites



REAL TIME AMR SURVEILLANCE DEPLOYING BIOMERIEUX SOLUTIONS





« MAKE I.T REAL »

PIONEERING DIAGNOSTICS